{'fraction_non_alphanumeric': 0.014749262536873156, 'fraction_numerical': 0.0029498525073746312, 'mean_word_length': 5.994845360824742, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
General Anesthesia With and Without Remifentanil for Flexible and Rigid Bronchoscopy: A Retrospective Case-Matched Study.

Prior research suggests general anesthesia (GA) with remifentanil is superior to GA without remifentanil regarding perioperative outcomes, including the postanesthesia care unit (PACU) length of stay (LOS). The objective of this study was to compare the intraoperative management and PACU LOS in patients who underwent GA with or without remifentanil for bronchoscopy. The study included 5,763 adult patients who underwent flexible bronchoscopy and received GA with or without remifentanil or who underwent rigid bronchoscopy and received GA with or without remifentanil. Despite prolonged procedural length in both the flexible and rigid bronchoscopy groups and greater ASA score in the flexible bronchoscopy group, no difference in the adjusted PACU LOS or time to extubation was found. Remifentanil was associated with hemodynamic perturbations and desaturation events. Remifentanil was associated with a significant reduction in nonremifentanil opioid requirements. Although both groups receiving remifentanil were associated with a less favorable intraoperative hemodynamic profile, remifentanil did not increase the incidence of postoperative complications despite that group having a greater ASA score and procedural duration.